Oxivir® Tb disinfectant kills SARS-CoV-2 (COVID-19 virus) in 1 minute
The Therapeutic Goods Administration (TGA) has recognised disinfectants as critical in preventing the spread of COVID-191.
Diversey Australia and New Zealand are proud to announce Oxivir® Tb (Accelerated Hydrogen Peroxide® (AHP®) based formulation) is now approved with the label claim “Kills SARS-CoV-2 (COVID-19 virus) in 1 minute”.
This new claim is in addition to the current comprehensive list of virucidal, bactericidal and fungicidal claims under ARTG 164850 for Oxivir Tb Wipes, standard, large, refill wipes and ARTG 165058 for Oxivir Tb Ready to Use (RTU) Liquid. In addition our Oxivir® Five 16 and Virex® II are now also approved with the label claim ‘Kills SARS-CoV-2 (COVID-19 virus)’. This new claim is in addition to the current comprehensive list of claims under ARTG 286618 for Oxivir® Five 16 and ARTG 153031 for Virex II.
“As a global leader in the cleaning and hygiene industry Diversey Australia is working tirelessly to supply our valued customers with products which assist to limit the spread of COVID-19. I would like to extend my gratitude to our ANZ Technical team who have gained TGA approvals to add this additional claim against COVID-19. This claim brings greater confidence to the various sectors we service including Healthcare, Hospitality, BSC and Retail.” Said Wayne Hill, Managing Director, Diversey ANZ.
The selection of the right disinfectant is critical. Oxivir® Tb is low odour, sustainable, biodegradable yet a powerful alternative to bleach and quat based disinfectants. AHP has dual safety and efficacy profiles and should be considered for surface disinfection on high touch areas during the COVID-19 epidemic. The active ingredient, hydrogen peroxide, breaks down to water and oxygen.
Oxivir Tb is patient friendly and safe for staff, while being gentle on most surfaces. Oxivir Five 16 is an Accelerated Hydrogen Peroxide® (AHP®) based hospital grade cleaner disinfectant effective against a wide variety of pathogenic micro-organisms including viruses, bacteria, antibiotic-resistant bacteria, fungi, mould and mildew.
Oxivir Five 16 kills pathogens including VRE, MRSA, Klebsiella, Acinetobacter, Pseudomonas, E.coli, Norovirus, Hepatitis B, Influenza A, RSV, Human Coronavirus 229E. Kills SARS-CoV-2 (COVID-19 virus). Oxivir Five 16 delivers fast, effective cleaning and disinfecting performance in one step.
Virex II is low odour quaternary based hospital grade disinfectant cleaner that provides broad spectrum germicidal activity and kills SARS-CoV-2 (COVID-19 virus), HIV-1, HBV, VRE, MRSA, Avian Influenza Type A, Human Coronavirus 229E, controls mould and mildew and more.
“As cases of COVID-19 grow, the demand and urgency for cleaning and disinfection requirements has reached unprecedented levels. It was important we worked with the Australian TGA to add the COVID-19 claim to our Oxivir Tb, Oxivir Five 16 and Virex II range of products. It was also important we communicate this information to our valued customers. Whilst we celebrate this announcement, our stock level challenges persist due to unprecedented demands. We ask for patience as we service multiple essential services including healthcare and aged care facilities”. Noted Debbie Walker, Marketing Manager ANZ.
Diversey has been, and always will be, a pioneer and facilitator for life. We constantly deliver revolutionary cleaning and hygiene technologies that provide total confidence to our customers across all of our global sectors.
Reference: 1. https://www.tga.gov.au/appropriate-use-disinfectants-information-consumers-health-professionals-and-healthcare-facilities
2nd February 2021
